PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
In case of gastric cancer, the incidence of HER-2 positivity (2+, 3+ on IHC and/or FISH (+))
is reported as similar as that of breast cancer, that is 22% of all cases. A recent ToGA
Trial, phase III trial comparing trastuzumab combined with chemotherapy
(fluoropyrimidine+cisplatin) versus chemotherapy alone in chemotherapy-naïve HER-2 (+)
gastric cancer shows the significant benefit of using trastuzumab in terms of overall
survival and progression-free survival. It provides the clinical evidence of HER-2 as a
reasonable and potential therapeutic target in gastric cancer.
Nowadays, lapatinib, HER-1 and HER-2 dual inhibitor, is also testing under the clinical trial
in gastric cancer.
In preclinical study, PF-00299804 is highly active in HER-2 amplified gastric cancer cell
lines.(SNU preclinical data) So, we plan this phase II trial of PF-00299804 monotherapy in
patients with HER-2 positive advance gastric cancer after failure of at least one
chemotherapy regimen.